Companies 0 See All
Hedge Funds 0 See All
Insiders 0 See All
Institutional Investors 0 See All
Click here to see all results for
Home > Insider Trading > Filing (0001209191-21-025846)

Filing Details

Accession Number:
0001209191-21-025846
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-04-07 16:08:40
Reporting Period:
2021-03-29
Accepted Time:
2021-04-07 16:08:40
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1681682 Endra Life Sciences Inc. NDRA Electromedical & Electrotherapeutic Apparatus (3845) 260579295
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1706297 Milos Michael Thornton 3600 Green Court, Suite 350
Ann Arbor MI 48105		 Chief Technology Officer No Yes No No
Reported Non-Derivative Transactions
Show Other Fields >>
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2021-03-29 18,750 $2.37 274,960 No 4 S Direct
Common Stock Disposition 2021-04-07 15,000 $2.53 259,960 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Show Other Fields >>
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Options Acquisiton 2021-04-05 50,000 $0.00 50,000 $2.64
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
50,000 2031-04-05 No 4 A Direct
Footnotes
  1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.35 to $2.39, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.56, inclusive. The reporting person undertakes to provide to ENDRA Life Sciences Inc., any security holder of ENDRA Life Sciences Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. This stock option grant becomes exercisable in three equal annual installments beginning April 5, 2022.